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Abstract
Rationale Numerous preclinical and clinical studies have re-
ported the rapid and sustained antidepressant effects of the
NMDA receptor antagonist ketamine. Because ketamine in-
duces several undesirable and dangerous effects, a variety of
strategies have been suggested to avoid such effects.
Objectives Here, we propose to enhance the sub-effective
doses of ketamine by co-administration with the group II me-
tabotropic glutamate (mGlu) receptor antagonist LY341495.
This compound potentially acts as an antidepressant via a
mechanism similar to that of ketamine.
Methods To investigate the rapid and sustained antidepressant-
like effects of these drugs, we administered ketamine and
LY341495 individually or in combination, 40 min and 24 h be-
fore the forced swim test (FST).
Results We found that sub-effective doses of ketamine and
LY341495, given jointly, induce significant antidepressant-
like effects, at both 40 min and 24 h after administration.
The results obtained using Western blot technique indicate
that mammalian target of rapamycin (mTOR) pathway activa-
tion may be involved in the mechanism of this action. The
effects of drugs, used at identical ranges of times and doses,
on spontaneous locomotor activity in rats were excluded.
Furthermore, the results obtained from the rota-rod test and
the ketamine-induced hyperlocomotion test suggest a lack of
potentially adverse effects from the combined administration
of ketamine and LY341495 at doses previously used in the
FST.
Conclusion Altogether, these data suggest that the joint ad-
ministration of ketamine and LY341495 might be a notewor-
thy alternative to the use of solely ketamine in the therapy of
depression.
Keywords Antidepressant . Depression . Forced swim test .
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Introduction
The current treatment of depression is based on the modula-
tion of biogenic amine systems and requires the long-term
administration (3–6 weeks) of antidepressant drugs (ADs) in
order to obtain positive therapeutic effects (Millan 2006). On
the other hand, several clinical studies have shown that sub-
anesthetic doses of a noncompetitive NMDA antagonist, ke-
tamine, can induce fast relief of depressive symptoms, which
lasts for a few days or a week in patients affected by major
depressive disorder (MDD) (Berman et al. 2000; Phelps et al.
2009; Rasmussen et al. 2013; Zarate et al. 2006).
Accumulating evidence also points to the rapid and sustained
antidepressant-like activity of ketamine in rodent behavioral
models of depression, including the forced swim test (FST),
the tail suspension test (TST), the learned helplessness para-
digm, and chronic mild stress (CMS) (Garcia et al. 2008,
2009; Gigliucci et al. 2013; Koike et al. 2011; Li et al. 2010;
Maeng et al. 2008). One of the leading hypotheses to explain
the unique antidepressant properties of ketamine suggests that
ketamine affects extracellular glutamate release, resulting in
the enhancement of AMPA receptor activation and the subse-
quent increase in the release of BDNF. Consequently, BDNF
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stimulates TrkB receptors and leads to fast activation of the
mammalian target of rapamycin (mTOR) signaling pathway,
resulting in the augmentation of the synaptogenesis in the
prefrontal cortex (PFC) (Duman et al. 2012; Li et al. 2010).
According to this hypothesis, enhanced synaptogenesis as a
result of the activation of the mTOR cascade appears to be a
key mechanism of the rapid and sustained antidepressant ac-
tion of ketamine. Interestingly, several studies have shown
that functional synaptic changes in the PFC, which appear
24 h after ketamine administration, correlate with the antide-
pressant effects of the drug in animal models of depression
(Koike et al. 2011; Li et al. 2010; Maeng et al. 2008).
Thus, it appears that ketamine could become a breakthrough
treatment for depression. However, we note that the use of keta-
mine can lead to dangerous consequences, including dissociative
and pro-psychotic side effects. Moreover, due to its hallucino-
genic properties, ketamine may be overused (Pal et al. 2002). In
addition, ketamine not only stimulates psychosis in patients suf-
fering from schizophrenia but also induces psychosis-like states
in previously healthy patients, which limits its usage as anAD for
outpatients (Krystal et al. 1998; Lathi et al. 1995; Malhotra et al.
1996). To overcome these limitations, several new pharmacolog-
ical strategies have been proposed, including enhancement of the
therapeutic effects of ketamine by combining its administration
with other antidepressant agents, e.g., lithium (Chiu et al. 2014;
Liu et al. 2013).
Numerous studies have shown that antagonists of group II
metabotropic glutamate (mGlu) receptors (including mGlu2
and mGlu3 subtypes), MGS0039 and LY341495, evoke cer-
tain effects that resemble the effects of ketamine. For example,
these drugs induce rapid and prolonged antidepressant-like
effects in the FST and the TST (Chaki et al. 2004; Koike
and Chaki 2014; Pałucha-Poniewiera et al. 2010, 2014), and
the mechanism of their antidepressant action is related to
AMPA receptor stimulation, activation of the mTOR pathway,
and the synthesis of synaptic proteins in the PFC (Dwyer et al.
2012; Karasawa et al. 2005; Koike et al. 2011; Koike and
Chaki 2014). In contrast, behavioral studies suggest that group
II mGlu receptor antagonists will not induce serious adverse
effects that are typical of ketamine. Because the unique actions
of ketamine and the group II mGlu receptor antagonist might
both be associated with stimulation of the same molecular
pathways, we hypothesized that LY341495 could enhance
the antidepressant-like effects of ketamine, while undesirable
ketamine-induced effects will not be induced.
Therefore, in the present study, we investigated whether
joint administration of low, sub-effective doses of ketamine
and LY341495 exhibit both acute (40 min after single
injection) and prolonged (24 h after single injection)
antidepressant-like activity in the FST of rats. The second
aim of this experiment was to assess a profile of the potential
adverse effects of this combination. The last goal of the study
was to investigate if mTOR pathway and synaptic protein
synthesis might be involved in the mechanism of action of a
combined administration of ketamine and LY341495.
Materials and methods
Animals and housing
Male Sprague-Dawley rats (weighing 250–350 g) obtained
from Charles River Laboratories, Germany were used in this
study. The animals were housed five per cage and maintained
under standard laboratory conditions of temperature (19–
21 °C) and lighting (light phase 6 a.m.–6 p.m.). Food and
water were available ad libitum. Each experimental group
consisted of seven to ten animals, and each rat was used only
once. Behavioral experiments were performed between 9 a.m.
and 2 p.m. by an experimenter unaware of the treatment. All
procedures were carried out in accordance with the criteria of
the National Institutes of Health Animal Care and Use
Committee and were approved by the Second Local Ethics
Committee in Krakow, at the Institute of Pharmacology,
Polish Academy of Sciences.
Drug administration
Ketamine hydrochloride solution (Bioketan, Biowet, Poland)
was diluted with 0.9 % NaCl, while LY341495 (Tocris
Cookson Ltd., Bristol, UK) was dispersed in a suspension of
0.5 % methylcellulose using an ultrasonic homogenizer
(Core-Parmer Instrument Co., Chicago, IL, USA). Control
groups received 0.9 % NaCl or 0.5 % methylcellulose. All
chemicals were administered intraperitoneally (IP) at a con-
stant volume of 1 ml/kg body weight.
The forced swim test
Two sessions of the experiment were performed according to
the procedure described by Porsolt et al. (1978), with some
necessary modifications. On the first day of the experiment,
rats were placed individually in glass cylinders (40 cm high,
18 cm in diameter) containing 25 cm of water that was main-
tained at 25 °C. The water column was sufficiently deep so
that the rats could not support themselves by placing their
paws on the base of the cylinder. After 15 min, the rats were
placed in a drying room (30 °C) for 30 min. The rats were
placed again in the cylinder 24.5 h later, and the total duration
of immobility was measured during the 5-min main test. The
following three different behaviors were rated: (1) immobili-
ty—rats were considered to be immobile when they remained
passively floating in the water; (2) swimming—rats were con-
sidered to be swimming if they were making active swimming
motions, more than necessary to solely maintain their head
above water; and (3) climbing—rats were considered to be
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climbing when they were making active movements in and
out of the water with their forepaws, usually directed against
the walls. Each parameter in the FSTwas measured manually
by an independent experimenter unaware of the treatment.
Ketamine, LY341495, a mixture of ketamine and LY341495,
or vehicle was administered IP 40 min or 24 h before the main
test.
Spontaneous locomotor activity
Spontaneous locomotor activity was recorded individually for
each animal in Opto-Varimex (Columbus Instruments,
Columbus, OH, USA) plexiglass chambers (43 × 44 ×
25 cm) connected to a compatible PC. Each cage was
surrounded by a 15 × 15 array of photocell beams located
3 cm from the floor surface. Interruptions of the photobeams
were interpreted as horizontal activity, and the distance trav-
eled was converted into centimeters. All the data were ana-
lyzed using Auto-track software (Columbus Instruments,
USA). The rats were administered IP injections of ketamine,
LY341495, a combination of the two drugs, or vehicle in their
home cages: 40 min or 24 h after drug administration, the rats
were placed individually into the clean locomotor activity
chambers. Immediately thereafter, locomotor activity was
measured every 5 min for 30 min.
Ketamine-induced hyperactivity
Ketamine-induced hyperactivity was measured using the
equipment previously used for evaluation of the exploratory
activity of rats. Rats were placed individually into actometers
for an acclimation period of 60 min. Then, they were admin-
istered an IP injection of ketamine, LY341495, a combination
of the two compounds, or vehicle. Immediately after injection,
each rat was returned into the chamber. From then on, the total
distance traveled was measured within a 60-min experimental
session and stored every 10 min.
Rota-rod test
The rota-rod test was performed in order to assess ketamine-
induced impairment of motor coordination. The procedure
was performed according to Vogel et al. (2008) with some
modifications. The rats were placed on the rota-rod apparatus
(ENV-577; Med Associates, St. Albans, VT) rotating at a con-
stant speed of 6 revolutions per minute (rpm). Three experi-
mental sessions were performed. During the first session, the
animals were individually placed on a rotating rod for 2 min. If
the rat fell off of the rod, it was placed on the rod again. The
second session, lasting 2 min, was performed 10 min after the
first session. During this session, each rat that fell off at least
twice was excluded from the experiment. The third experi-
mental session was carried out 2 h later. LY341495 was
administered 20 min before the test, whereas ketamine was
given 2 min before the test. The same schedule of treatment
was adopted when a combination of the two drugs was ad-
ministered. The total number of animals that fell off before the
end of this session was recorded and the latency to fall
(expressed in s) was measured.
Synaptosome preparation and Western blotting
Tissue samples were dissected from the PFC and hippocam-
pus and homogenized in ice-cold lysis buffer [0.32M sucrose,
20 mM HEPES (pH 7.4); 1 mM EDTA; 1× protease inhibitor
cocktail, 5 mM NaF, and 1 mM NaVO3]. Homogenates were
than centrifuged at 2800 rpm for 10 min at 4 °C. The resulting
supernatant was then centrifuged at 12,000 rpm for 10 min at
4 °C. The resulting pellets were sonicated in protein lysis
buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1 % Triton X-100, 0.1 % SDS, 2 mM EDTA, 1 mM NaVO3,
5 mMNaF, and protease inhibitor cocktail. Protein concentra-
tions were measured using a BCA kit (Thermo Scientific,
USA). Next, the proteins were separated by SDS-PAGE and
transferred to nitrocellulose membranes and blocked for 1 h in
1 % of blocking solution [BM Chemiluminescence Western
Blotting Kit (Mouse/Rabbit) made by Roche, Switzerland].
After blocking, the membranes were incubated overnight at
4 °C with the primary antibodies. The following antibodies
were used: mTOR (1:500), phospho-mTOR (pmTOR,
Ser2448, 1:500), p70S6K (1:500), phospho-p70S6K
(pp70S6K, Thr389, 1:200), GluA1 (1:1000), and PSD95
(1:1000)—all from Abcam, USA. On the following day, the
membranes were washed three times for 10 min in Tris-
buffered saline with Tween (TBS-T) and incubated for
30 min with anti-mouse/anti-rabbit-IgG-peroxidase-conjugat-
ed antibodies. This set of secondary antibodies was also a
component of the BM Chemiluminescence Western Blotting
Kit (Mouse/Rabbit) (Roche, Switzerland). After incubation,
the membranes were washed three times for 10 min with
TBS-T. In the last step, the blots were incubated with a detec-
tion reagent (Roche, Switzerland). The signal from the tested
proteins was visualized and measured using a Fuji-Las 1000
system and Fuji Image Gauge v.4.0 software. To check the
transfer and loading, β-actin was indicated on each blot. For
this purpose, a primary monoclonal antibody (Millipore,
Germany) was used. The final result is given as the ratio of
the optical density of particular proteins to the optical density
of β-actin.
Statistics
Statistical analyses were performed using GraphPad Prism
5.01 (GraphPad Software, San Diego, CA, USA). All the
results are expressed as the means ± SEM. Statistical signifi-
cance was assessed using a one-way ANOVA followed by
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Dunnett’s post hoc test (to evaluate dose–effect curves in the
FST) or a two-way ANOVA (when a drug combination was
used in the FST and for the rota-rod test results). A repeated-
measures ANOVAwas used to analyze the locomotor activity
results, and t test was used to analyze Western blotting data.
The results were considered statistically significant if p < 0.05.
More details concerning the statistical analysis are presented
beneath the figures.
Results
The antidepressant-like effects of ketamine in the FST
One-way ANOVA showed the effects of ketamine (3–30 mg/
kg, IP), administered 40 min before the FST, on immobility
time [F(3, 29) = 12.17, p < 0.0001; Fig. 1a], climbing time
[F(3, 29) = 8.904, p < 0.001; Fig. 1b], and swimming time
[F(3, 29) = 6.395, p < 0.01; Fig. 1c]. Post hoc tests showed that
ketamine, given at a dose of 10 mg/kg, significantly (p < 0.01)
changed the immobility time (Fig. 1a) and the swimming time
(Fig. 1c), whereas at the dose of 30 mg/kg, it affected all three
parameters: the immobility time (p < 0.001; Fig. 1a), the
climbing time (p < 0.001; Fig. 1b), and the swimming time
(p < 0.01; Fig. 1c). When applied at a dose of 3 mg/kg,
ketamine did not affect any of the tested parameters.
Concerning the antidepressant-like activity of ketamine (3–
50 mg/kg) administered 24 h before the FST, we observed the
effect of this drug on immobility time [F(4, 33) = 2.941,
p < 0.05; Fig. 1d] and swimming time [F(4, 33) = 2.899,
p < 0.05; Fig. 1f], without any effect on climbing [F(4,
33) = 0.262, p > 0.05; Fig. 1e]. Post hoc analyzes showed that
ketamine significantly decreased immobility time and
increased swimming time only when it was applied at a dose
of 10 mg/kg (p < 0.05; Fig. 1d, f).
The antidepressant-like effects of the group II mGlu
receptor antagonist LY341495 in the FST
A one-way ANOVA revealed that LY341495 (0.1–1 mg/kg,
IP) administered 40 min before the FST significantly reduced
immobility time [F(3, 33) = 10.98, p < 0.0001; Fig. 2a] and
increased swimming time [F(3, 33) = 8.894, p < 0.001;
Fig. 2c] but had no impact on climbing time [F(3, 33) =
1.499, p < 0.05; Fig. 2b]. The post hoc Dunnett test showed
that LY341495 given at doses of 0.3 and 1 mg/kg significantly
decreased the time of immobility (p < 0.01 and p < 0.001,
respectively; Fig. 2a) and increased the time of swimming
(p < 0.001 and p < 0.05, respectively; Fig. 2c). LY341495
given 40 min before the FST at the dose of 0.1 mg/kg failed
to exert any effect.
Fig. 1 The antidepressant-like effect of ketamine administered IP 40min
before the FST (upper panel) or 24 h before the FST (lower panel) in rats.
The following three parameters were measured: immobility (a, d),
climbing (b, e), and swimming (c, f). Values are expressed as the
means ± SEM and were analyzed by one-way ANOVA followed by
Dunnett’s post hoc test (*p < 0.05; **p < 0.01; ***p < 0.001 vs.
respective vehicle)
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When administered 24 h before the FST, LY341495
(0.3–1 mg/kg) significantly affected two parameters, im-
mobility time [F(2, 20) = 8.741, p < 0.01; Fig. 2d] and
swimming time [F(2, 20) = 13.76, p < 0.001; Fig. 2f],
without any effect on climbing [F(2, 20) = 0.16, p > 0.05;
Fig. 2e]. Post hoc analysis showed that LY341495
significantly decreased immobility (p < 0.01) and increased
swimming time (p < 0.001) after injection of a 1-mg/kg dose,
24 h before the test. No changes were observed for this
compound at the lower tested dose of 0.3 mg/kg, using the
same schedule of administration.
The effects of joint administration of ketamine
and LY341495 in the FST
The joint administration of sub-effective doses of keta-
mine and LY341495 was used in the FST, and 40 min or
24 h after IP administration, we evaluated both rapid and
sustained antidepressant effects. To study the rapid ef-
fect, the doses of 3 and 0.1 mg/kg, for ketamine and
LY341495, respectively, were selected for the experi-
ment. Four experimental groups were formed: a control
group, ketamine (3 mg/kg) and LY341495 (0.1 mg/kg)
groups, and a group given a mixture of ketamine and
LY341495. A two-way ANOVA revealed a strong impact
of LY341495 [F(1, 29) = 12.6, p < 0.01] and ketamine
[F(1, 29) = 11.53, p < 0.01] on the immobility of mice.
However, no interaction of the two parameters was ob-
served [F(1, 29) = 2.138, p > 0.05], despite the apparent
trend of decreased rat immobility by co-administration of
the two substances (Fig. 3a). Because we did not observe
a statistically significant interaction of both drugs, which
could be due to the tendency of ketamine (3 mg/kg) to
reduce immobility time, we decided to examine a lower
dose of the drug (1 mg/kg) in combination with
LY341495 (0.1 mg/kg). A two-way ANOVA analysis
revea led an in te rac t ion be tween ke tamine and
LY341495 for the sub-effective doses [F(1, 27) = 7.947,
p < 0.01], indicating a significant enhancement of the
rapid effect of ketamine by LY341495 in the FST
(Fig. 3a). Another experiment was designed to test
prolonged antidepressant effects (24 h after a single in-
ject ion) of sub-effect ive doses of ketamine and
LY341495. A two-way ANOVA revealed that non-
active doses of ketamine (3 mg/kg) and LY341495
(0.3 mg/kg), both administered 24 h before the FST,
significantly decreased the immobility time of rats when
administered jointly [F(1, 29) = 5.553, p < 0.05, Fig. 4a].
Such interaction indicates the enhancement of the
sustained antidepressant-like effects of ketamine by
LY341495. Separate analyses for the swimming time
and climbing time results revealed no interactions
Fig. 2 The antidepressant-like effect of LY341495 administered IP
40 min (upper panel) or 24 h (lower panel) before the FST in rats. The
following three parameters were measured: immobility (a, d), climbing
(b, e), and swimming (c, f). Values are expressed as the means ± SEM and
were analyzed by one-way ANOVA followed by Dunnett’s post hoc test
(*p < 0.05; **p < 0.01; ***p < 0.001 vs. respective vehicle)
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between ketamine and LY341495. However, we did ob-
serve that joint administration 40 min before the test
tended to increase the time of swimming (Fig. 3c).
The effects of ketamine and LY341495 on the spontaneous
locomotor activity of rats
Ketamine administered at doses of 10 or 50 mg/kg 40 min
before the test did not significantly change the spontaneous
locomotor activity of rats ([F(1, 11) = 1.191, p > 0.05] and
[F(1, 11) = 0.412, p > 0.05], respectively; Fig. 5a). When we
analyzed the influence of ketamine (10 or 50 mg/kg) injected
24 h before the locomotor activity test, we also noticed a lack
of effect of this treatment on the distance traveled ([F(1, 10) =
2.14, p > 0.05] and [F(1, 10) = 0.06, p > 0.05], respectively;
Fig. 5b). Another experiment aimed to measure the locomotor
activity of rats treated with ketamine, LY341495, and the
combination of these drugs, at the doses previously used in
the FST, both 40 min and 24 h after injection. We found no
significant changes between control rats and rats injected with
ketamine (3 mg/kg) [F(1, 14) = 2.382, p > 0.05], LY341495
(0.3 mg/kg) [F(1, 14) = 0.685, p > 0.05], or the mixture of
these drugs [F(1, 19) = 0.312, p > 0.05], when measured
40 min after injection (Fig. 6a). Similarly, no changes in the
spontaneous locomotor activity of rats were observed 24 h
after single administration of ketamine (3 mg/kg) [F(1,
12) = 2.842, p > 0.05], LY341495 (0.3 mg/kg) [F(1, 14) =
4.167, p > 0.05], or the combination of these compounds
[F(1, 14) = 4.443, p > 0.05].
The effect of joint administration of ketamine
and LY341495 on the stimulation of the mTOR signaling
pathway in the rat PFC and hippocampus
To investigate whether ketamine and LY341495, given
jointly at doses that induced a sustained antidepressant-
like effect in rats, stimulate mTOR signaling, we exam-
ined the influence of tested compounds on the total and
phosphorylated forms of mTOR and p70S6K in the
synaptosome-enriched fraction of the PFC 40 min or
24 h after injection. Ketamine at a dose of 10 mg/kg
was used as a positive reference group. The density of
the obtained bands for phosphorylated and total forms of
the studied proteins were first normalized to β-actin
bands, and then, the ratio of the normalized phospho/
total forms was calculated for each protein. Statistical
analysis of Western blot results in the PFC showed that
ketamine (3 mg/kg) and LY341495 (0.3 mg/kg) given
jointly 40 min before decapitation induced a significant
increase in the phosphorylated forms of mTOR (p < 0.05)
and p70S6K (p < 0.01) compared with a control group,
by 178 and 222 %, respectively (Fig. 7a, b). The similar
Fig. 4 The antidepressant-like effect of joint administration of ketamine
and LY341495 injected IP 24 h before the FST in rats. The following
three parameters were measured: immobility (a), climbing (b), and
swimming (c). Values are expressed as the means ± SEM and were
analyzed by two-way ANOVA. *p < 0.05 interaction: ketamine
(3 mg/kg) × LY341495 (0.3 mg/kg)
Fig. 3 The antidepressant-like effect of joint administration of ketamine
and LY341495 injected IP 40 min before the FST in rats. The following
three parameters were measured: immobility (a), climbing (b), and
swimming (c). Values are expressed as the means ± SEM and were
analyzed by two-way ANOVA. **p < 0.01 interaction: ketamine
(1 mg/kg) × LY341495 (0.1 mg/kg)
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effect was produced by ketamine (10 mg/kg) which induced a
significant increase in both pmTOR (p < 0.05) and pp70S6K
(p< 0.0001), by 219 and 275 %, respectively (Fig. 7a, b). The
similar but weaker effects were observed in the hippo-
campus, where a mixture of ketamine (3 mg/kg) and
LY341495 (0.3 mg/kg) induced a noticeable but not sta-
tistically significant increase in the level of phosphory-
lated forms of both mTOR (p > 0.05) and p70S6K
(p > 0.05), by 139 and 155 %, respectively (Fig. 8a, b).
At the same time, ketamine (10 mg/kg) produced a sig-
nificant increase in the phosphorylated forms of both
mTOR (p < 0.05) and p70S6K (p < 0.05), by 154 and
178 % (Fig. 8a, b).
Fig. 5 The effect of ketamine on the spontaneous locomotor activity of
rats during a 30-min experimental session. Ketamine was administered IP
40 min (a) or 24 h (b) before the test. A1 and B1 represent schedules of
the experimental procedures. A2 and B2 show the respective results.
Values are expressed as the means ± SEM and were evaluated by
repeated-measures ANOVA
Fig. 6 The effect of joint administration of ketamine and LY341495 on
the spontaneous locomotor activity of rats during a 30-min experimental
session. The compounds were administered IP 40 min (a) or 24 h (b)
before the test. A1 and B1 represent schedules of the experimental
procedures. A2 and B2 show the respective results. Values are
expressed as the means ± SEM and were evaluated by repeated-
measures ANOVA
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The effect of joint administration of ketamine
and LY341495 on the synaptic protein expression
in the rat PFC and hippocampus
To determine whether a mixture of ketamine and
LY341495, used at the doses that had previously result-
ed in a positive effect in the FST, influence synaptic
protein expression in the PFC and hippocampus, we
investigated the influence of the tested compounds on
the expression levels of GluA1 and PSD-95 in the
synaptosome-enriched fraction of the PFC or hippocam-
pus. Western blot analysis showed no effect of a mix-
ture of ketamine and LY341495 on the expression level
of GluA1 protein in the PFC both 40 min and 24 h
after administration of drugs (p > 0.05; Fig. 9a).
Ketamine used at a dose of 10 mg/kg did not also
induce any effect on the expression level of GluA1,
both 40 min and 24 h after administration (Fig. 9a).
However, a statistically significant increase in the ex-
pression level of PSD-95 was observed in the PFC in
a group of rats pre-treated with ketamine (10 mg/kg),
24 h after administration (p < 0.05; Fig. 9b). At the
same time, a combined administration of ketamine and
LY341495 did not induce any changes in the expression
level of PSD-95 in any tested time point (40 min or
24 h after administration; Fig 9b). In contrast, we found
a significant increase in hippocampal levels of both
GluA1 (p < 0.05) and PSD-95 (p < 0.01), by 139 and
138 % respectively, 24 h after ketamine (10 mg/kg)
administration and no changes in the level of both
GluA1 and PSD-95 40 min after ketamine injection
(p > 0.05; Fig. 10a, b). A mixture of ketamine and
LY341495 induced a significant increase in the level
of PSD-95 (p < 0.01) by 138 %, while it did not
Fig. 7 The effect of joint administration of ketamine (3 mg/kg) and
LY341495 (0.3 mg/kg) on the stimulation of the mTOR signaling
determined by Western blot analysis of pmTOR, mTOR, pp70S6K, and
p70S6K in the synaptosome-enriched fraction of the rat PFC. The density
of the obtained bands for phosphorylated and total forms of the studied
proteins were first normalized to β-actin bands, and then, the ratio of the
normalized phospho/total forms was calculated for each protein. The data
were analyzed by t test comparing the expression values between vehicle-
treated group (VEH) and ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-
treated group (KET + LY) or ketamine (10 mg/kg)-treated group (KET
10). Values (the means ± SEM) are expressed as percentage of changes
vs. control levels (n = 8; *p < 0.05, **p < 0.01, ****p < 0.0001 vs.
vehicle)
Fig. 8 The effect of joint administration of ketamine (3 mg/kg) and
LY341495 (0.3 mg/kg) on the stimulation of the mTOR signaling
determined by Western blot analysis of pmTOR, mTOR, pp70S6K, and
p70S6K in the synaptosome-enriched fraction of rat hippocampus. The
density of the obtained bands for phosphorylated and total forms of the
studied proteins were first normalized to β-actin bands, and then, the ratio
of the normalized phospho/total forms was calculated for each protein.
The data were analyzed by t test comparing the expression values
between vehicle-treated group (VEH) and ketamine (3 mg/kg) +
LY341495 (0.3 mg/kg)-treated group (KET + LY) or ketamine
(10 mg/kg)-treated group (KET 10). Values (the means ± SEM) are
expressed as percentage of changes vs. control levels (n = 8; *p < 0.05
vs. vehicle)
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influence the hippocampal level of GluA1, both 40 min
and 24 h after administration (p > 0.05; Fig. 10a).
Ketamine-induced hyperlocomotion test
In rats previously acclimatized to actometers for 60 min, ke-
tamine, at doses of 10 and 30 mg/kg, IP induced a rapid in-
crease in the locomotor activity ([F(1, 14) = 6.799, p < 0.05]
and [F(1, 14) = 26.4, p < 0.001], respectively) (Fig. 11). When
used at a dose of 30 mg/kg, the effect of ketamine-induced
hyperactivity reached a peak 20 min after injection and then
gradually decreased (Fig. 12a). Next, we aimed to investigate
whether a combination of ketamine and LY341495 doses,
which had previously resulted in a positive effect in the FST,
can induce behavioral effects in the ketamine-induced
hyperlocomotion test. We found that ketamine (3 mg/kg) ad-
ministered separately or in a combination with LY341495
(0.3 mg/kg) did not induce any effect in this test ([F(1,
14) = 1.133, p > 0.05] and [F(1, 14) = 1.03, p > 0.05], respec-
tively). LY341495 (0.3 mg/kg), administered separately, also
did not produce any hyperlocomotion, compared to control
rats [F(1, 14) = 0.356, p > 0.05] (Fig. 12b).
Ketamine-induced motor coordination impairment
To study the effect of a combination of ketamine and LY341495,
used at doses that had previously resulted in a positive effect in the
FST, on motor coordination, four experimental groups were
formed: a control group, ketamine (3 mg/kg) and LY341495
(0.3 mg/kg) groups, and a group given a mixture of the two. A
two-way ANOVA showed lack of interaction between ketamine
(3mg/kg) and LY341495 (0.3mg/kg) [F(1, 30) = 1.112; p> 0.05;
Fig. 13], suggesting that ketamine action was not enhanced by
LY341495 in this test. Furthermore, the results suggested an op-
posite tendency, i.e., the motor coordination of ketamine
(3 mg/kg)-treated rats seemed to be improved by LY341495
Fig. 9 The effect of joint administration of ketamine (3 mg/kg) and
LY341495 (0.3 mg/kg) on the expression of synaptic proteins: GluA1
(a) and PSD-95 (b) in the rat PFC. The density of the obtained bands of
the studied proteins was normalized to β-actin bands. The data were
analyzed by t test comparing the expression values between vehicle-
treated group (VEH) and ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-
treated group (KET + LY) or ketamine (10 mg/kg)-treated group (KET
10). Values (the means ± SEM) are expressed as percentage of changes
vs. control levels (n = 8; *p < 0.05 vs. vehicle)
Fig. 10 The effect of joint administration of ketamine (3 mg/kg) and
LY341495 (0.3 mg/kg) on the expression of synaptic proteins: GluA1
(a) and PSD-95 (b) in rat hippocampus. The density of the obtained bands
of the studied proteins was normalized to β-actin bands. The data were
analyzed by t test comparing the expression values between vehicle-
treated group (VEH) and ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-
treated group (KET + LY) or ketamine (10 mg/kg)-treated group (KET
10). Values (the means ± SEM) are expressed as percentage of changes
vs. control levels (n = 8; *p < 0.05, **p < 0.01 vs. vehicle)
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(0.3 mg/kg) pretreatment. To deeply analyze this problem, a
higher dose of ketamine was used in the experiment (10 mg/
kg). A two-way ANOVA revealed that ketamine (10 mg/kg)
significantly reduced the latency to fall from the rotating rod
[F(1, 30) = 233; p< 0.0001; Fig. 13] and the pretreatment with
LY341495 (0.3 mg/kg) did not change this effect (a lack of inter-
action between ketamine (10 mg/kg) and LY341495 (0.3 mg/kg)
was found [F(1, 30) = 0.614; p< 0.05; Fig. 13]). The number of
rats that fell off from the rotating rod during a 2-min experimental
session was also recorded. In the group of control rats, 3 out of 11
animals (27 %) fell off of the rod, while in the groups of animals
treated with ketamine (10 mg/kg) or ketamine (10 mg/kg) plus
LY341495 (0.3 mg/kg), 100 % of the rats (n= 8) fell off during
the same experimental period. The percentages of rats that fell
from the rotating rod in the remaining experimental groups were
56 % in the group administered a 3-mg/kg dose of ketamine,
27 % in the group treated with LY341495 (0.3 mg/kg), and
27 % in the group treated with the combination of the two drugs.
Discussion
The objective of our study was to investigate whether a group
II mGlu receptor antagonist, LY341495, enhances the rapid
and sustained antidepressant-like effects of ketamine. The
FST in rats was chosen for this study, as this test is one of
the most widely used in animal models for estimating
Fig. 11 a Exemplary immunoblots of mTOR, pmTOR, p70S6K,
pp70S6K, GluA1, PSD-95, and β-actin from the PFC of vehicle-treated
group (V), ketamine (3 mg/kg) + LY341495 (0.3 mg/kg)-treated group (K
+ L), and ketamine (10 mg/kg)-treated group (K). The tissue was
collected 40 min after drugs administration. b Exemplary immunoblots
of mTOR, pmTOR, p70S6K, pp70S6K, GluA1, PSD-95, and β-actin
from hippocampus of vehicle-treated group (V), ketamine (3 mg/kg) +
LY341495 (0.3 mg/kg)-treated group (K + L), and ketamine (10 mg/kg)-
treated group (K). The tissue was collected 40 min after drugs
administration. c Exemplary immunoblots of GluR1, PSD95, and β-
actin from the PFC of vehicle-treated group (V), ketamine (3 mg/kg) +
LY341495 (0.3 mg/kg)-treated group (K + L), and ketamine (10 mg/kg)-
treated group (K) The tissue was collected 24 h after drug administration.
d Exemplary immunoblots of GluR1, PSD95, and β-actin from
hippocampus of vehicle-treated group (VEH), ketamine (3 mg/kg) +
LY341495 (0.3 mg/kg)-treated group (KET + LY), and ketamine
(10 mg/kg)-treated group (KET 10). The tissue was collected 24 h after
drug administration
Fig. 12 The effect of ketamine given separately (a) or jointly with
LY341495 (b) on the locomotor activity of rats during a 60-min
experimental session. Measurements started immediately after IP
injections of tested substances. A1 and B1 represent schedules of the
experimental procedures. A2 and B2 show the respective results. Values
are expressed as the means ± SEM and were evaluated by repeated-
measures ANOVA. *p < 0.05; ***p < 0.001 vs. control group
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antidepressant-like activity of new potential ADs (Porsolt
et al. 1978; Cryan et al. 2005). Here, we applied a modified
version of the FST, originally introduced by Detke et al.
(1995), in which three specific types of behavior were mea-
sured: immobility, climbing, and swimming. Previous studies
suggest that climbing is sensitive to catecholamine-based
ADs, whereas swimming is modified byADs, acting via mod-
ulation of the serotonergic system, including selective seroto-
nin reuptake inhibitors (SSRIs) (Detke et al. 1995; Page et al.
1999). To summarize, the time of immobility is the main pa-
rameter that indicates the antidepressant activity of a tested
compound, while the times of climbing and swimming only
suggest the possible mechanisms of the compound’s action.
Two time schedules were used in the current study, 40min and
24 h after single injection of a drug, which reflect the rapid and
prolonged effect, respectively. The first aim of this study was
to determine the dose–effect curves for ketamine and
LY341495 to identify the effective and sub-effective doses
of both compounds. Dose-dependent antidepressant-like ef-
fects of ketamine and LY341495 have been previously report-
ed using several rodent models of depression, including the
FST (Chaki et al. 2004; Dwyer et al. 2012; Garcia et al. 2008,
Gigliucci et al. 2013; Maeng et al. 2008; Koike et al. 2011;
Koike and Chaki 2014; Li et al. 2010; Pałucha-Poniewiera
et al. 2010).
In the FST, the antidepressant-like effect of classic ADs
(including the SSRIs, MAO inhibitors, and tricyclics) is rapid
and appears after short-term administration (three injections,
24, 5, and 1 h before the test) or even after single injection
(usually 30–60 min before the test) (Borsini and Meli 1988).
However, the therapeutic effect in depressive patients appears
after several weeks of treatment. Thus, a dose-dependent an-
tidepressant-like effect of ketamine and LY341495, which
was well noticeable 40min after single IP administration, only
suggests the antidepressant activity of these drugs but does not
suggest anything about the expected rate of emergence of a
therapeutic effect in patients. Interestingly, both ketamine and
LY341495 induced a significant and dose-dependent increase
in the time of swimming, suggesting the involvement of the
serotonergic system in this action. These results confirm the
study by Gigliucci et al. (2013), who reported that ketamine
induces sustained antidepressant-like activity via a serotonin-
dependent mechanism. The results of our study also indicate
that ketamine at the highest tested dose of 30 mg/kg affected
climbing, indicating that the mechanism of its antidepressant
activity also involves modulation of noradrenergic and/or do-
paminergic systems. Based on the results obtained during de-
termination of the dose–effect curves, sub-effective doses of
both substances (3 mg/kg for ketamine and 0.1 mg/kg for
LY341495) were chosen for joint administration. This drug
combination induced strong antidepressant-like effects in the
FST; however, a two-way ANOVA did not find any signifi-
cant interaction between the tested drugs, indicating a lack of
statistical significance. Because we observed a tendency for
ketamine to decrease immobility time in this experiment, we
decided to use an even lower dose of this drug and combine it
with LY341495. At a dose of 1 mg/kg, ketamine did not
change any behavioral parameter in the FST; however, keta-
mine significantly decreased immobility time when combined
with LY341495 (0.1 mg/kg). These results clearly show that
LY341495 enhances the rapid antidepressant activity of keta-
mine in the FST.
A separate set of experiments were performed in order to
analyze the sustained antidepressant effects of the tested com-
pounds. As previously mentioned, the prolonged antidepres-
sant activity of ketamine and LY341495 in animal models of
depression, including the FST, has been proposed to be related
to functional synaptic changes in the PFC, which appear 24 h
after single administration of the drug (Dwyer et al. 2012;
Gigliucci et al. 2013; Li et al. 2010; Koike et al. 2011;
Koike and Chaki 2014; Pałucha-Poniewiera et al. 2014). It is
worth mentioning that other dosages proposed by other au-
thors did not allow for the observation of the effectiveness of
this drug (Bechtholt-Gompf et al. 2011; Popik et al. 2008;
Yilmaz et al. 2002). Therefore, we applied a 24-h time lag
between drug administration and behavioral testing, as a mod-
el of a sustained antidepressant effect of the tested
compounds.
In the current study, we have shown that ketamine admin-
istered 24 h before the FST induced an antidepressant-like
effect at only one tested dose, 10 mg/kg. Both lower (3 mg/
kg) and higher (30 and 50 mg/kg) doses of ketamine were
inactive in this test, although a marked tendency was observed
that showed reduced immobility time after a dose of 30 mg/kg.
It is interesting that similar effects of ketamine in the FST 24 h
after injection have been published previously by Li et al.
(2010), who showed that ketamine induced a strong
Fig. 13 The effect of ketamine given separately or jointly with
LY341495 on the latency to fall during the rota-rod test in rats. Values
are expressed as the means ± SEM and were analyzed by two-way
ANOVA. ***p < 0.0001 vs. vehicle
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antidepressant-like effect at a dose of 10 mg/kg, while it was
completely inactive at a dose of 80 mg/kg.
The second drug used in this study, LY341495, induced a
strong antidepressant-like effect in the FSTwhen administered
24 h before the test at a dose of 1 mg/kg, which changed two
behavioral parameters, immobility and swimming. At a dose
of 0.3 mg/kg, LY341495 did not induce any effect. Based on
the dose–response curves, the doses of 3 mg/kg for ketamine
and 0.3 mg/kg for LY341495 were chosen as sub-effective
and were injected jointly 24 h before the FST in order to
investigate the potential antidepressant-like activity of this
combination. The results have shown that joint administration
of the tested compounds induced a significant decrease in the
immobility time, thus indicating an antidepressant-like effect.
Compounds that increase locomotor activity can provide
false positive results in the FST. Thus, another experiment in
this study was designed to investigate the effect of the tested
compounds, used at doses and schedules of applications pre-
viously applied in the FST, on the spontaneous locomotor
activity of rats. We did not observe any changes in the spon-
taneous locomotor activity in rats, both 40 min and 24 h after
administration of the tested doses of ketamine or LY341495,
given individually or in combination. Thus, we conclude that
the behavioral effects observed in the FST did not result from
a general hyperactivity of rats but reflected the antidepressant
activity of the tested compounds.
To investigate the possible mechanism of a sustained
antidepressant-like effect of a combined administration of ke-
tamine (3mg/kg) and LY341495 (0.3mg/kg), we analyzed the
influence of this combination on the mTOR pathway and syn-
aptic protein level in two brain areas, possibly involved in this
action: the PFC and hippocampus. It has been established that
activated mTOR phosphorylates the p70-kDa ribosomal pro-
tein S6 (p70S6K), which in turn induces the phosphorylation
of the eukaryotic initiation factor (eIF4B), leading to the ini-
tiation of protein translation (Crino 2011). Thus, phosphory-
lation of mTOR and its downstream substrate, p70S6K, con-
stitute robust biomarkers for the activation of the mTOR sig-
naling pathway. Numerous data have indicated that ketamine,
used at a dose that induces a sustained antidepressant-like
effect (10 mg/kg), transiently activates mTOR signaling in
rats. Such effect has been observed in the PFC 30 min to 1 h
after ketamine administration (Li et al., 2010; Zhou et al.,
2014) and in hippocampus 30 min after ketamine administra-
tion (Yang et al., 2013; Zhou et al., 2014). It has been pro-
posed that ketamine-induced activation of mTOR pathway
might be a crucial mechanism involved in the sustained anti-
depressant effects of ketamine (Li et al., 2010, Duman et al.,
2012). Therefore, in this study, ketamine (10 mg/kg) has been
used as a positive reference control. Since the similar activa-
tion of mTOR pathway has been observed in the rat PFC 1 h
after single injection of LY341495, used at doses that produce
a sustained antidepressant-like effect (Dwyer et al., 2012), we
assumed that the activation of mTOR cascade and a subse-
quent increase in the level of synaptic proteins might be a
mechan i sm poss ib ly invo lved in the sus ta ined
antidepressant-like activity of a mixture of sub-effective doses
of ketamine and LY341495 used in the study. Here we show
that combined administration of ketamine and LY341495, at
doses that induce a sustained antidepressant-like effect, pro-
duced a significant increase in the phosphorylation of both
mTOR and p70S6K in the PFC and a noticeable tendency to
increase these factors in the hippocampus of rats, indicating
the involvement of mTOR pathway in the antidepressant-like
effect of a mixture of ketamine and LY341495. The lack of
statistical significance in hippocampus may partially result
from a large scatter of results between individual rats in this
group. Expression of selected synaptic proteins (GluA1 and
PSD-95) has been also analyzed in the PFCs and hippocampi
of rats administered with the mixture of ketamine (3 mg/kg)
and LY341495 (0.3 mg/kg), and in a group of rats injected
with solely ketamine (10 mg/kg), used as a reference control.
We have found no changes in the level of synaptic proteins in
hippocampus or the PFC, 40 min after IP injection of tested
drugs. These results are in agreement with previously pub-
lished data showing that ketamine, at a dose of 10 mg/kg,
induced no changes in the expression level of synaptic pro-
teins 30 min after injection and in the case of most proteins
also 1 h after administration (Li et al., 2010). On the other
hand, 24 h after treatment, we observed a significant increase
in the protein level of GluA1 in the hippocampus and in the
level of PSD-95 in the PFC and hippocampus, in rats admin-
istered with ketamine 10 mg/kg, thus partially confirming pre-
vious results of other authors (Li et al. 2010; Dwyer et al.,
2012). A significant discrepancy between our data and the
results of the Duman’s group is a lack of effect of ketamine
on the level of GluA1 protein in the PFC, which we observed
also in a repeat experiment (data not shown). Some methodo-
logical differences may account for these discrepancies.
Importantly, a mixture of ketamine (3 mg/kg) and LY341495
(0.3 mg/kg), which was shown to induce a sustained
antidepressant-like effect, similar to ketamine (10 mg/kg)
did not influence expression level of any tested synaptic pro-
tein in the PFC but it induced a strong increase in the expres-
sion level of PSD-95 in the hippocampus, without affecting
GluA1 level in this brain structure. On the basis of these re-
sults, we conclude that although a joint administration of
LY341495 and ketamine, at doses that induce a sustained
antidepressant-like effects in the FST, induces a rapid and
robust activation of mTOR pathway in the PFC, it does not
produce any increase in the level of any tested synaptic protein
in this brain area. Thus, the enhanced level of GluA1 or PSD-
95 in the PFC does not seem to be involved in the sustained
antidepressant-like effect of a combined administration of
sub-effective doses of tested compounds used in this study.
On the other hand, it seems that in hippocampus, both jointly
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given ketamine and LY341495 as well as solely ketamine,
used as a reference control (10 mg/kg), induce weaker effects
on the mTOR pathway activity. However, a significant in-
crease in the level of both tested synaptic proteins (GluA1
and PSD-95) has been observed 24 h after ketamine treatment
and in the case of PSD-95 also after the combined adminis-
tration of ketamine and LY341495. Therefore, it seems that
the increased level of expression of PSD-95 protein hippo-
campus might be involved in the mechanism of
antidepressant-like activity of the mixture of ketamine and
LY341495 used in the study. Explanation of the mechanism
of the antidepressant effects of sub-effective doses of keta-
mine and LY341495 requires further investigation.
In the last stage of this study, we focused on the side
effect profile of the tested compounds. Systemic admin-
istration of the noncompetitive NMDA antagonists, such
as MK-801, phencyclidine (PCP), and ketamine, to ro-
dents causes a complex behavioral response called PCP-
like effects, which include enhanced locomotion, body
rolling, sniffing, and disturbances of motor coordination
(Carter 1995). For our study, we choose two behavioral
tests that may be considered as models of undesirable
effects caused by ketamine. First, we used the ketamine-
induced hyperlocomotion test. Ketamine and other
NMDA antagonist, including MK-801, cause rapid hy-
peractivity in rats (Andine et al. 1999). It is believed
that this effect resembles the attention deficit hyperac-
tivity observed in humans after taking psychostimulants.
Because antipsychotics selectively reduce this behavior,
the hyperactivity induced by MK-801 is widely used as
a model of positive symptoms of schizophrenia (Andine
et al. 1999). Here, we observed significant hyperactivity
induced by 30 mg/kg ketamine that peaked 20 min after
ketamine administration in rats previously adapted to an
actometer for 1 h. A smaller but still statistically signif-
icant effect of hyperactivity was induced by ketamine at
a dose of 10 mg/kg. Such an activity profile confirms
earlier studies on ketamine-induced hyperlocomotion
(Gilmour et al. 2009). Subsequent studies showed a lack
of an effect of lower doses of ketamine (1–3 mg/kg),
LY341495 (0.3 mg/kg), or a combination of ketamine
(3 mg/kg) with LY341495 (0.3 mg/kg) on the hyperac-
tivity of rats. Thus, it seems that the combined admin-
istration of ketamine and LY341495, at doses that pre-
viously induced antidepressant-like effect in the FST,
did not produce psychotomimetic-like effects in the
ketamine-induced hyperlocomotion test. The lack of ad-
verse effects of this drug combination is also suggested
by the results of the rota-rod test, which is used as
standard test for estimating motor coordination.
Ketamine at a dose of 3 mg/kg, injected separately or
in combination with LY341495 (0.3 mg/kg), did not
significantly change the motor coordination of rats. At
the same time, ketamine at a higher dose of 10 mg/kg
strongly disturbed the motor coordination of all tested
rats in this group, decreasing the latency to fall from the
rota-rod by c.a. 90 %. This effect was not changed by
LY341495 (0.3 mg/kg) pretreatment.
In conclusion, in this study, we found that the group II
mGlu receptor antagonist LY341495 enhances the
antidepressant-like effect of ketamine in the behavioral de-
spair model of depression, indicating that the therapeutic dose
of ketamine could be markedly reduced by its co-
administration with LY341495 (a mGlu2/3 antagonist). Joint
administration of these drugs might be a noteworthy alterna-
tive to the use of ketamine alone, which has dangerous con-
sequences, such as addiction, when given at higher doses.
Furthermore, our results encourage further examination of
group II mGlu antagonists in humans, because its action
seems to be similar to that of ketamine, but it lacks the adverse
effects of noncompetitive NMDA receptor antagonists.
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